Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Market Reports

ASX Market Report

Fixed Interest
Close Points
Currency Close Points
All Ordinaries 5742 39 0.69 $A vs $US 0.7550 -- -0.00
S&P/ASX 200 5706 40 0.71 $A vs GBP 0.5959 0.0004 0.06
10-year Bond Rate 2.42 -0.01 -0.62 $A vs YEN 83.84 -0.20 -0.24
  $A vs EUR 0.6762 0.0001 0.02
  $A vs $NZ 1.0407 -0.0008 -0.07
PREMIUM To view this information
become a Premium Member
ASX Code Company Name Impact Recommendation
CAR Limited (CAR)
MTS Metcash Limited (MTS)
TWE Treasury Wine Estates Limited (TWE)
WES Wesfarmers Limited (WES)
WOW Woolworths Limited (WOW)
GMG Goodman Group (GMG)

Thursday 22 June - The Australian market ended its two-day losing streak today as bargain hunters piled into the big four banks and other oversold blue-chip stocks, despite another overnight fall in the US market and oil prices. At close, the ASX 200 index recovered half of yesterday's losses, finishing slightly above the key 5,700-point mark. There were positive results across the sectors, with the only exception of telecommunication services. The Australian dollar depreciated against the greenback and had mixed results against other major currencies.

The All Ordinaries added 39.10 points (0.69%) to 5,742.30 while the S&P/ASX 200 gained 40.30 points (0.71%) to 5,706.00.

CIMIC Group Limited (CIM)

CIMIC Group announced that CPB Contractors, with its JV partners, has been selected to deliver a new metro railway crossing deep under the world-famous Sydney Harbour. The NSW Government awarded a $2.81bn contract to deliver twin 15.5km tunnels and associated civil works on Stage 2 of the Sydney Metro project - Australia's public transport project. The JV comprises CPB Contractors (45%), John Holland (45%) and Ghella (10%). In June 2016, CPB Contractors, with JV partners John Holland and Dragados, officially completed tunnels and station civil works for the $8.3bn Sydney Metro Northwest project (Stage 1 of Sydney Metro) seven months ahead of the contract program. CIM climbed 65 cents (1.69%) to $39.13.

Mesoblast Limited (MSB)

Mesoblast announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial of its proprietary allogeneic Mesenchymal Precursor Cells (MPCs) in patients with biologic refractory rheumatoid arthritis (RA) were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology. The abstract was selected by peer review and presented by the trial's independent investigators. The EULAR Congress is the key European platform for showcasing innovation in rheumatology and highlighting the latest advances in the field. The 2017 Congress was attended by 14,000 delegates from more than 120 countries. MSB rose 4 cents (2.02%) to $2.02.

The NZX rose 36.58 points (0.49%) to 7,563.69 while the Nikkei fell 28.28 points (-0.14%) to close at 20,110.51.

The Australian dollar was last quoted at 75.50 US cents.

Companies commencing Ex-Dividend Trading Today (ASX 300):

G8 Education Limited

© 2017 Morningstar. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information at You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO").

ASX Today

Recent Analyst Reports